We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at ...

As at December 2024, Regulus Therapeutics had cash of US$76m and no debt. Looking at the last year, the company burnt through US$42m. That means it had a cash runway of around 22 months as of December ...

Regulus Therapeutics Inc.’s RGLS share price has surged by 11.28%, which has investors questioning if this is right time to ...

Regulus Therapeutics Inc ( ($RGLS) ) has released its Q4 earnings. Here is a breakdown of the information Regulus Therapeutics Inc presented to ...

Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce ...

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $12.8 million in its fourth quarter. On a per-share basis, the San Diego-based company said it ...

Regulus Therapeutics stock opened at $1.35 on Monday. The company’s 50 day simple moving average is $1.31 and its 200 day simple moving average is $1.48. Regulus Therapeutics has a fifty-two ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $12.8 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a ...